On the other hand, in people with type 2 diabetes, although exendin 9-39 did not alter fasting insulin secretion, the response to hyperglycemia was decreased so that mean secretion rate in the final hour of the clamp was decreased (0.54 ± 0.07 nmol/min versus 0.44 ± 0.05 nmol/min, P = 0.04 [Figure 4D]) as was the integrated incremental response to hyperglycemia. The gene discussed is INS; the disease is type 2 diabetes mellitus.